Causes of Graft Loss After Kidney Transplantation Following Rabbit-Antithymocyte Gobulin Induction and Steroid-Sparing Maintenance.

Kim, J.; Watkins, Anthony C.; Aull, Meredith J.; Serur, David; Hartono, Choli; Kapur, Sandip

doi:10.1097/00007890-201407151-00450

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kidney transplantation (KT) remains the optimal treatment for patients with end-stage renal disease (ESRD) [1]. Nevertheless, infection after KT is still an important limitation for graft and patient outcomes [2][3][4]. One of the most common infections with negative impact post-transplantation is tuberculosis (TB) [5].…”

Section: Introductionmentioning

confidence: 99%

Mycobacterium Tuberculosis Infection after Kidney Transplantation: A Comprehensive Review

et al. 2022

View full text Add to dashboard Cite

Tuberculosis (TB) in kidney transplant (KT) recipients is an important opportunistic infection with higher incidence and prevalence than in the general population and is associated with important morbidity and mortality. We performed an extensive literature review of articles published between 1 January 2000 and 15 June 2022 to provide an evidence-based review of epidemiology, pathogenesis, diagnosis, treatment and outcomes of TB in KT recipients. We included all studies which reported epidemiological and/or outcome data regarding active TB in KT, and we approached the diagnostic and treatment challenges according to the current guidelines. Prevalence of active TB in KT recipients ranges between 0.3–15.2%. KT recipients with active TB could have a rejection rate up to 55.6%, a rate of graft loss that varies from 2.2% to 66.6% and a mortality rate up to 60%. Understanding the epidemiological risk, risk factors, transmission modalities, diagnosis and treatment challenges is critical for clinicians in providing an appropriate management for KT with TB. Among diagnostic challenges, which are at the same time associated with delay in management, the following should be considered: atypical clinical presentation, association with co-infections, decreased predictive values of screening tests, diverse radiological aspects and particular diagnostic methods. Regarding treatment challenges in KT recipients with TB, drug interactions, drug toxicities and therapeutical adherence must be considered.

show abstract